Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial

Addition of ravulizumab to BSC did not improve survival or other secondary outcomes.
Safety findings were consistent with the known safety profile of ravulizumab in its
approved indications. Despite the lack of efficacy, the study adds value for future
research into complement therapeutics in critical illnesses by showing that C5 inhibition
can be accomplished in severely ill patients.

Related Keywords

France ,Mendon ,Massachusetts ,United States ,Japan ,United Kingdom ,Boston ,Helsinki ,Eteläuomen Läi ,Finland ,Spain ,American ,Jonathan Monteleone Alexion ,Dassule Alexion ,Senhwa Biosciences ,Mary Greenacre ,Mark Ma Alexion ,Arshad Mujeebuddin Alexion ,Stephan Ortiz ,Alanna Mceneny Alexion ,Children Discovery Institute ,Amgen ,American Society Of Clinical Investigation ,York Heart Association ,Life Foundation ,Novartis ,Pfizer ,Samsung ,Astrazeneca ,Health Survey Physical Component Summary ,University Of Pittsburgh ,Piper Medical Communications ,Elsevier Ltd ,Philips ,Us Department Of Defense ,Us National Institutes Of Health ,American Thoracic Society ,Novo Nordisk ,Astrazeneca Rare ,Good Clinical Practice ,International Council ,Technical Requirements ,Human Use ,Dis Ther ,New York Heart Association ,Astrazeneca Rare Disease ,Almac Clinical Technologies ,Organ Failure Assessment ,Scare Med ,Common Terminology Criteria ,Adverse Events ,Medical Dictionary ,Regulatory Activities ,Medical Outcomes Study Short Form ,Health Survey ,Physical Component Summary ,Mental Component Summary ,Alexion Clinical Trials Disclosure ,Transparency Policy ,Discovery Institute ,Longer Life Foundation ,American Society ,Ambient Clinical Analytics ,Silence Therapeutics ,Jonathan Monteleone ,Arshad Mujeebuddin ,Alanna Mceneny ,